All In Biotech

Drug Trial Radar · NCT05917938

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Hepatic Impairment and Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Jul 4, 2023

Primary completion

Dec 16, 2024

Study completion Dec 16, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study medicine NNC0194-0499 is under development for non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). All participants will receive a single dose of 30 milligram (mg) of the study medicine. The study medicine will be given in the form of an injection of 0.6 millilitres in a skinfold of the thigh (subcutaneous). The study will last for up to 64 days. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Women who are able to become pregnant must use highly effective contraception and will be counselled on the use of contraception. Participants with impaired liver function will undergo an ultrasound of the belly and measurement of brain activity.

Conditions

  • Hepatic Impairment
  • Healthy Volunteers

Interventions

  • NNC0194-0499Drug

    NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-∞, Single Dose, NNC0194-0499: the area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single doseTime frame: From 0 hours (Day 1) until end of study visit (Day 36)

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • APEX Research

    München, Germany

  • Uniwersyteckie Centrum Kliniczne (UCK)

    Gdansk, Poland

  • Cardiomedicum Sp. z o.o.

    Krakow, Poland

  • Summit Clinical Research s.r.o.

    Bratislava, Slovakia

  • Summit Clinical Research s.r.o.

    Malacky, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.